Carcinoma, Renal Cell Clinical Trials

205 clinical trials for Carcinoma, Renal Cell across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) — RECRUITING · PHASE3
• Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — RECRUITING · PHASE1
• Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations — RECRUITING
• Autologous Dendritic Cell Vaccine in Kidney Cancer — RECRUITING · PHASE2
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — RECRUITING · PHASE1
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer — RECRUITING · PHASE1
• Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC — RECRUITING · PHASE1
• Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma — RECRUITING
• Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT — RECRUITING
• Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells — RECRUITING
• Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion — RECRUITING
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) — ACTIVE_NOT_RECRUITING · PHASE3
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) — ACTIVE_NOT_RECRUITING · PHASE1
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) — ACTIVE_NOT_RECRUITING · PHASE1
• Savolitinib vs. Sunitinib in MET-driven PRCC. — ACTIVE_NOT_RECRUITING · PHASE3
• An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) — COMPLETED
• A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) — COMPLETED · PHASE1
• A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) — ACTIVE_NOT_RECRUITING · PHASE3
• Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors — COMPLETED · PHASE1
• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma — COMPLETED · PHASE1
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) — COMPLETED
• Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma — NOT_YET_RECRUITING · NA
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment — TERMINATED · PHASE3
• DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies — TERMINATED · PHASE1
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer — TERMINATED · PHASE2
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) — TERMINATED · PHASE2
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study — ACTIVE_NOT_RECRUITING · PHASE3
• Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers) — ACTIVE_NOT_RECRUITING
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma — COMPLETED · PHASE3
• Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma — COMPLETED · PHASE2
• A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) — ACTIVE_NOT_RECRUITING · PHASE2
• Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study). — TERMINATED
• A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney — COMPLETED · PHASE3
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs — WITHDRAWN
• A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology — COMPLETED · PHASE1
• Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing — COMPLETED · PHASE2
• A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine. — COMPLETED
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. — COMPLETED
• Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma — OTHER · PHASE2
• Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma — TERMINATED · PHASE1
• A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies — OTHER · PHASE1
• Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types — COMPLETED · PHASE2
• Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma — COMPLETED
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) — COMPLETED · PHASE3

Refine this search